PerformanceRiskValuationProfitabilityCashflowLiquidityESGRevenue & Geographic ExposureForecastFinancial GrowthIncome GrowthCashflow GrowthBalance Sheet Growth
Actinium Pharmaceuticals, Inc. (ATNM)
1.780.01 (-0.56%)
1.75 - 1.81
1.03 - 2.41
122.5K / 296.7K (Avg.)
-1.36 | -1.31
Identifies how quickly the company is scaling its balance sheet (via acquisitions, expansions, or debt). Strong growth, accompanied by sound fundamentals, can support long-term intrinsic value—while disproportionate debt expansion or bloated intangible assets can signal elevated risk.
-1.07%
Cash & equivalents declining -1.07% while AVXL's grows 9.62%. Howard Marks would question why our liquidity is shrinking while competitor builds cash.
No Data
No Data available this quarter, please select a different quarter.
-1.07%
Below half of AVXL's 9.62%. Michael Burry might suspect a liquidity shortfall if there's no alternative capital plan.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
-1.07%
Below half of AVXL's -41.13%. Michael Burry could suspect a liquidity squeeze. Verify operational performance.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
-1.07%
Below half of AVXL's -93.53%. Michael Burry sees a potential red flag for stagnation or capital shortage.
29.45%
50-75% of AVXL's 51.46%. Bruce Berkowitz notes the company is paying suppliers faster or not stretching terms as competitor does.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
21.08%
50-75% of AVXL's 28.40%. Bruce Berkowitz notes the firm keeps current liabilities growth relatively low.
6.41%
Higher Long-Term Debt Growth compared to AVXL's zero value, indicating worse performance.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
6.41%
Higher Total Non-Current Liabilities Growth compared to AVXL's zero value, indicating worse performance.
No Data
No Data available this quarter, please select a different quarter.
11.06%
Less than half of AVXL's 28.40%. David Dodd sees far fewer liability expansions relative to competitor.
No Data
No Data available this quarter, please select a different quarter.
-3.15%
Below half AVXL's -41.51%. Michael Burry suspects major net losses or high dividends vs. competitor.
No Data
No Data available this quarter, please select a different quarter.
382.94%
Less than half of AVXL's -100.00%. David Dodd notes simpler yoy equity changes vs. competitor.
-11.47%
Below half AVXL's -36.51%. Michael Burry sees potential underperformance in building shareholder capital.
-1.07%
Below half AVXL's -93.53%. Michael Burry sees significant shrinkage or inactivity vs. competitor.
No Data
No Data available this quarter, please select a different quarter.
6.41%
Less than half of AVXL's 19.59%. David Dodd sees less overall debt expansion vs. competitor.
6.78%
Less than half of AVXL's 19.64%. David Dodd sees better deleveraging or stronger cash buildup than competitor.